CAS 1187594-09-7

Baricitinib

Descrição:

Baricitinib é um medicamento de molécula pequena utilizado principalmente para o tratamento da artrite reumatoide moderada a severa. Funciona como um inibidor seletivo das enzimas Janus quinase (JAK), especificamente JAK1 e JAK2, que desempenham um papel crucial nas vias de sinalização de várias citocinas envolvidas em processos inflamatórios. A fórmula química de Baricitinib é C16H17N3O2, e tem um peso molecular de aproximadamente 285,33 g/mol. A substância aparece como um pó cristalino branco a off-white e é solúvel em dimetilsulfóxido (DMSO) e ligeiramente solúvel em água. Baricitinib é administrado por via oral e demonstrou reduzir os sinais e sintomas da artrite reumatoide ao modular a resposta imunológica. Sua farmacocinética indica uma meia-vida relativamente longa, permitindo a dosagem uma vez ao dia. Como qualquer medicamento, os efeitos colaterais potenciais incluem aumento do risco de infecções, elevações das enzimas hepáticas e alterações nas contagens de células sanguíneas, necessitando de monitoramento durante o tratamento.

Fórmula: C₁₆H₁₇N₇O₂S

InChI: InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)

Chave InChI: InChIKey=XUZMWHLSFXCVMG-UHFFFAOYSA-N

SMILES: C(C#N)C1(CN(S(CC)(=O)=O)C1)N2C=C(C=N2)C3=C4C(=NC=N3)NC=C4

Sinónimos:

• 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile
• 2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
• 2-(3-(4-(7H-Pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
• 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-
• Incb 028050
• Incb 28050
• Incb028050
• Ly 3009104
• Ly3009104
• Olumiant
• Baricitinib
• 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile Baricitinib (LY3009104, INCB028050)
• Baricitinib(INCB 028050
• aricitinib (LY3009104, INCB028050)
• Baricitinib (LY3009104)
• Baricitinib/INCB 028050/LY3009104
• Baricitinib (LY3009104, INCB028050)

1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile

CAS: 1187594-09-7

Fórmula: C₁₆H₁₇N₇O₂S

Pureza: 99%

Cor e Forma: Solid

Peso molecular: 371.4169

Ref: IN-DA003A5U

Baricitinib

CAS: 1187594-09-7

Baricitinib

Pureza: ≥98%

Peso molecular: 371.42g/mol

Ref: 54-BUP15488

Baricitinib

CAS: 1187594-09-7

Fórmula: C₁₆H₁₇N₇O₂S

Cor e Forma: White To Off-White Solid

Peso molecular: 371.42

Ref: 4Z-B-154001

Baricitinib

CAS: 1187594-09-7

Cor e Forma: Neat

Ref: 86-MM3905.00

Baricitinib

CAS: 1187594-09-7

Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.

Fórmula: C₁₆H₁₇N₇O₂S

Pureza: 99% - >99.99%

Cor e Forma: Solid

Peso molecular: 371.42

Ref: TM-T2485

Baricitinib

CAS: 1187594-09-7

Fórmula: C₁₆H₁₇N₇O₂S

Pureza: ≥ 98.0%

Cor e Forma: White to off-white solid

Peso molecular: 371.4

Ref: 7W-GW9910

Baricitinib

Produto Controlado

CAS: 1187594-09-7

Applications Baricitinib is a JAK1 and JAK2 inhibitor and have been used as a promising treatment for rheumatoid arthritis.
References Greenwald, L.J., et al.: Int. J. Clin. Rheumatol., 6, 401 (2011); Fridman, J.S., et al.: J. Immunol., 184, 5298 (2010);

Fórmula: C₁₆H₁₇N₇O₂S

Cor e Forma: White Solid

Peso molecular: 371.42

Ref: TR-B118690

Baricitinib

CAS: 1187594-09-7

Baricitinib is a Janus kinase inhibitor (JAK) currently used as monotherapy in the treatment of rheumatoid arthritis. Barictinib is also recommened for the treatment of atopic dermatitis and systemic lupus erythematosus. In mice interestingly, the administration of baricitinib reduced the inflammatory effects induced by a high-sugar diet on the metabolism.

Fórmula: C₁₆H₁₇N₇O₂S

Pureza: Min. 95%

Cor e Forma: Powder

Peso molecular: 371.42 g/mol

Ref: 3D-FE30357

Baricitinib - Bio-X ™

CAS: 1187594-09-7

Baricitinib is a Janus kinase inhibitor (JAK) currently used as monotherapy in the treatment of rheumatoid arthritis. Barictinib is also recommened for the treatment of atopic dermatitis and systemic lupus erythematosus. In mice interestingly, the administration of baricitinib reduced the inflammatory effects induced by a high-sugar diet on the metabolism.
Baricitinib is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Fórmula: C₁₆H₁₇N₇O₂S

Pureza: Min. 95%

Cor e Forma: Powder

Peso molecular: 371.42 g/mol

Ref: 3D-BB184033

BARICITINIB

CAS: 1187594-09-7

Fórmula: C₁₆H₁₇N₇O₂S

Pureza: 95%

Cor e Forma: Solid

Peso molecular: 371.42

Ref: 10-F468368

Baricitinib Azetidine-d4

Produto Controlado

CAS: 1187594-09-7

Fórmula: C₁₆H₁₃D₄N₇O₂S

Cor e Forma: Neat

Peso molecular: 375.44

Ref: TR-B118694